Τίτλος:
Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background:Metastatic RCC (mRCC) treatment has been revolutionized with 11 approved targeted agents. We report patterns of practice, outcomes and pharmacoeconomic analyses after the introduction of targeted therapy. Patients and methods: CRISIS was a retrospective multicenter study of mRCCpatients who received targeted therapy. Results were related to the start of 1st-line therapy, with a cut off at 1 January 2011 in order to depict the impact of increased availability of effective options. Results: 164 patients, were included. 70.1% and 44.5% received 2nd and 3rd-line therapy, respectively. More patients were treated in 2nd-line after 1 January 2011. After a median follow-up of 55.1 months, median progression-free (PFS) and overall survival (OS) were 10.7 (95% confidence intervals [CI]: 8.3–13.7), 7.3 (95% CI: 5.1–8.6), 5.8 (95% CI: 3.8–7.8) and 34 (95% CI: 28.5–39.8), 22.4 (95% CI: 16–32.1), 18.3 (95% CI: 12.4–26.4) months for first, second and third line, respectively. Efficacy of sunitinib and pazopanib in 1st-line were similar. The mean total cost/patient was 35,012.2 Euros (standard deviation [SD]: 28,971.5). Conclusions: Our study confirms previous real-world data suggesting that continuing advances in the treatment of mRCC produce favorable outcomes in everyday practice. Pharmacoeconomic analyses are important for cost-effective utilization of emerging novel therapies. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
Συγγραφείς:
Tsironis, G.
Koutsoukos, K.
Athanasakis, K.
Tsiara, A.
Tzannis, K.
Gerolympou, M.
Visvikis, A.
Oikonomopoulos, G.
Kollia, A.
Giannopoulou, E.
Dimitra, M.
Kostouros, E.
Papatsoris, A.
Dellis, A.
Stravodimos, K.
Varkarakis, I.
Samantas, E.
Aravantinos, G.
Kentepozidis, N.
Christodoulou, C.
Bozionelou, V.
Dimopoulos, M.A.
Bamias, A.
Περιοδικό:
Expert Review of Pharmacoeconomics and Outcomes Research
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
axitinib; everolimus; nivolumab; pazopanib; sorafenib; sunitinib; antineoplastic agent; pazopanib; pyrimidine derivative; sulfonamide; sunitinib, adult; adverse outcome; alopecia; anemia; Article; cancer survival; cardiotoxicity; controlled study; cost benefit analysis; cost effectiveness analysis; diarrhea; drug cost; drug efficacy; drug safety; fatigue; female; hair discoloration; hand disease; human; hypertension; hypothyroidism; kidney metastasis; liver toxicity; major clinical study; male; middle aged; mucosa inflammation; multicenter study; nausea and vomiting; nephrotoxicity; neurotoxicity; neutropenia; outcome assessment; overall survival; peripheral edema; practice guideline; progression free survival; retrospective study; skin manifestation; skin toxicity; survival rate; survival time; taste disorder; thrombocytopenia; thrombosis; aged; clinical practice; clinical trial; disease free survival; economics; follow up; Greece; kidney tumor; metastasis; molecularly targeted therapy; pharmacoeconomics; procedures; renal cell carcinoma; statistics and numerical data; very elderly, Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease-Free Survival; Economics, Pharmaceutical; Female; Follow-Up Studies; Greece; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Practice Patterns, Physicians'; Pyrimidines; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate
DOI:
10.1080/14737167.2019.1546121
